Ascendis Pharma's second quarter was the moment the three-product rare-endocrine franchise stopped being a story about a single product and started being a story about a portfolio. Total revenue reached €339 million ($391 million), up 115% year over year, but the more interesting line is buried lower: YORVIPATH revenue roughly doubled and a half (+145%), SKYTROFA returned to growth (+9%) after a year of flatlining, and YUVIWEL - launched in March after its February FDA approval - contributed its first full quarter of €8 million ($9 million) of revenue. Three products, each on its own trajectory, each contributing to a single income statement that just delivered €220 million ($254 million) of IFRS operating profit and a swing from a €53 million loss a year ago.
The GAAP print carries two non-recurring items that obscure the underlying turn. The €158 million ($183 million) cash gain from selling the rare pediatric disease Priority Review Voucher (PRV) awarded with the YUVIWEL approval moved into other operating income, and a €679.6 million recognition of previously unrecognized deferred tax assets - driven by a reassessment of recoverability against the now-positive earnings outlook - flowed into the income-tax line. Strip those out and the second quarter still produced a €92 million ($106 million) non-IFRS operating profit at a 27% margin, compared to a €23 million loss a year earlier. That is the cleanest read on the underlying franchise: a swing to non-IFRS profitability, on a 115% revenue print, three quarters after the lead product launched in the U.S.
The capital structure changed in the same quarter. On May 6 the company completed the optional redemption of all $575 million of 2.25% convertible notes due 2028, with every holder converting into 3.6 million ordinary shares. On April 20 a mandatory exchange of all American Depositary Shares (ADS) for ordinary shares closed, collapsing the dual-class structure into a single class trading on the Nasdaq Global Select Market. Three weeks later, after the June 26 close, Ascendis was added to the Russell 3000, 1000, 2500 and Midcap indexes. The May conversion and June index inclusion, taken together, are the formal steps by which the equity graduated from a small-cap development story to a mid-cap commercial compounder.
A $120 million share repurchase program announced in January was fully deployed by mid-year - March: 254,027 shares at $236.16 ($60.0 million); May: 251,391 shares at $238.64 ($60.0 million); aggregate 505,418 shares at an average $237.40 for $120.0 million total - against a current market capitalization of roughly $16.3 billion at the August 13 close of $246.23. Ascendis ended the quarter with €812 million ($937 million) of cash and equivalents against €450 million ($519 million) of remaining borrowings - exclusively the Royalty Pharma synthetic-royalty funding agreements - for a net cash position of approximately $418 million, after the cash from the PRV sale and H1 operating cash flow of €274 million. The balance sheet no longer has the convertible overhang that depressed per-share metrics for two years.
The quarter's report frame is whether the underlying commercial franchise can grow through the loss of the one-time PRV, the depletion of the deferred tax benefit, and the step-up in SG&A from continued launch investment. YORVIPATH at $1.16 billion annualized run-rate, SKYTROFA stabilizing, and YUVIWEL ramping from a four-month-old launch is the read on the underlying business; the next twelve months test whether the non-IFRS operating-margin trajectory holds above 20% as the PRV and convert-related items annualize out.